Redefining treatment paradigms in first-line advanced non-small cell lung cancer

Metastatic Non-small-cell lung cancer is still a devastating disease; however, treatment options have diversified dramatically in the past two decades. From unselected platinum-based chemotherapy for all patients, several different treatment groups have evolved i.e. those with "druggable" targets, those with a promising immune signature and those without any predicting factors outlined in this manuscript. Challenge include the intersections between these groups and the optimal treatment path. These issues will be addressed in this review.